Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123